Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Oct 02, 2024 12:50pm
69 Views
Post# 36250210

RE:RE:RE:RE:Moderna's CEO Stephan Bancel comments on mRNA cancer vaccine

RE:RE:RE:RE:Moderna's CEO Stephan Bancel comments on mRNA cancer vaccineSeptember 12, 2024 - Last month Moderna was hoping for a quick green light for its personalised neoantigen immunotherapy mRNA-4157, but that hope evaporated on September 12th. The company disclosed during its R&D day that the FDA “has not been supportive” of accelerated approval in adjuvant melanoma based on current data on the Merck-partnered project – which includes a recent three-year update from its phase 2 trial, Keynote-942.

The FDA’s issue with mRNA-4157 is unclear but it’s possible that, with the melanoma sector already well served, the agency is waiting for a clear overall survival benefit.

This is in contrast to ONCY's pelareorep which has demonstrated statistically significant PFS and survival data in its Phase 2 Goblet-1 HR+/HER2- metastatic breast cancer clinical study, in a segment of breast cancer that remains an unmet treatment need, in which the FDA would grant an Accelerated Approval. 
<< Previous
Bullboard Posts
Next >>